Roivant Sciences Ltd ROIV Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$33.53 down $0.51, 1.50% at close Oct 16
Last close · Previous close $34.04
- Market cap
- At the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.47Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$33.53down $0.51, 1.50%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$34.04Oct 15
- Volume4.92MOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume7.01MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $17.28 to $42.50; now $33.53
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ROIV beat the S&P 500 in 4 of 6 periods.
| Period | ROIV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ROIV: down 15.3% S&P 500: up 1.5% | ROIV trailed the S&P 500 by 16.8 percentage points Trailed |
| 3M | ROIV: down 1.2% S&P 500: up 1.9% | ROIV trailed the S&P 500 by 3.1 percentage points Trailed |
| YTD | ROIV: up 54.5% S&P 500: up 12.8% | ROIV beat the S&P 500 by 41.7 percentage points Beat |
| 1Y | ROIV: up 96.0% S&P 500: up 16.8% | ROIV beat the S&P 500 by 79.2 percentage points Beat |
| Long term | ||
| 3Y | ROIV: up 229.0% S&P 500: up 81.5% +48.7% vs +22.0% a year | ROIV beat the S&P 500 by 147.5 percentage points Beat |
| 5Y | ROIV: up 457.0% S&P 500: up 83.1% +41.0% vs +12.9% a year | ROIV beat the S&P 500 by 373.9 percentage points Beat |
$10,000 invested in ROIV 5 years ago (Oct 15, 2021) would be worth about $55,698 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $18,305.
ROIV beat the S&P 500 in 4 of 6 periods.
| Period | ROIV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ROIV: down 15.3% S&P 500: up 1.2% | ROIV trailed the S&P 500 by 16.5 percentage points Trailed |
| 3M | ROIV: down 1.2% S&P 500: up 1.7% | ROIV trailed the S&P 500 by 2.9 percentage points Trailed |
| YTD | ROIV: up 54.5% S&P 500: up 11.9% | ROIV beat the S&P 500 by 42.6 percentage points Beat |
| 1Y | ROIV: up 96.0% S&P 500: up 15.5% | ROIV beat the S&P 500 by 80.5 percentage points Beat |
| Long term | ||
| 3Y | ROIV: up 229.0% S&P 500: up 75.0% +48.7% vs +20.5% a year | ROIV beat the S&P 500 by 154.0 percentage points Beat |
| 5Y | ROIV: up 457.0% S&P 500: up 71.2% +41.0% vs +11.4% a year | ROIV beat the S&P 500 by 385.8 percentage points Beat |
$10,000 invested in ROIV 5 years ago (Oct 15, 2021) would be worth about $55,698 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $17,118.
All-time high
$41.81
Closing high on . Now 19.8% below that record.
Split-adjusted daily closes since Oct 1, 2021.
Stock splits
ROIV hasn’t split since its price history begins in 2021.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY27, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $7.53Mdown 67.6%
- Net income
- −$266.25M
- Diluted EPS
- −$0.47
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY25 (Sep 30, 2024) | $4.48M | −$230.18M | −$0.31 |
| Q3 FY25 (Dec 31, 2024) | $9.02M | $169.38M | $0.23 |
| Q4 FY25 (Mar 31, 2025) | $7.57M | −$206.48M | −$0.29 |
| Q1 FY26 (Jun 30, 2025) | $2.17M | −$223.36M | −$0.33 |
| Q2 FY26 (Sep 30, 2025) | $1.57M | −$113.52M | −$0.17 |
| Q3 FY26 (Dec 31, 2025) | $2.00M | −$265.89M | −$0.38 |
| Q4 FY26 (Mar 31, 2026) | $2.52M | $302.99M | $0.34 |
| Q1 FY27 (Jun 30, 2026) | $1.44M | −$189.84M | −$0.26 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Mar 31, 2022) | $55.29M | −$845.26M | −$1.26 |
| FY23 (Mar 31, 2023) | $31.53M | −$1.01B | −$1.42 |
| FY24 (Mar 31, 2024) | $32.71M | $4.35B | $5.23 |
| FY25 (Mar 31, 2025) | $29.05M | −$171.98M | −$0.24 |
| FY26 (Mar 31, 2026) | $8.26M | −$299.77M | −$0.54 |
Margins
- Gross 81.2%
- Operating −7,914.8%
- Net −3,535.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$821.06MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$816.47MLast 12 months
- Capital spending$4.59MLast 12 months
- −10,901.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $314.75MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$314.75MLast 12 months
Balance sheet
- $4.29BAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$107.15MAs of Jun 30, 2026
- Net cash$4.18BAs of Jun 30, 2026
- 16.72As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.03As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 1 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −6.1%Last 12 months
Over the last 12 months, Roivant Sciences lost money: its net loss was 6.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −5.0%Last 12 months
Over the last 12 months, Roivant Sciences’s net loss was 5.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Roivant Sciences Ltd
Roivant Sciences Ltd
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bermuda
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ROIV news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ROIV stock FAQ
What is ROIV stock’s price today?
Roivant Sciences (ROIV) traded at $33.53 at the close on , down $0.51 (1.50%) from the previous close of $34.04. Over the past 52 weeks it has traded between $17.28 and $42.50.
If you invested $1,000 in ROIV 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ROIV on would be worth about $5,570 at the close on , a total return of +457.0%. The same $1,000 would be worth $1,960 if invested one year ago. Past performance doesn’t predict future returns.
What is ROIV’s P/E ratio?
ROIV’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.47).
How much revenue does Roivant Sciences make?
Roivant Sciences reported $7.5 million of revenue over the four quarters to , down 67.6% from the twelve months before. In its latest quarter (Q1 FY27, ended ) revenue was $1.4 million, down 33.5% from a year earlier.
Is Roivant Sciences profitable?
Not over the four quarters to . Roivant Sciences reported a net loss of $266.3 million across those four quarters on $7.5 million of revenue.
What are ROIV’s earnings per share?
ROIV’s diluted earnings per share were −$0.47 over the four quarters to , compared with −$0.70 in the twelve months before. The latest quarter (Q1 FY27) brought −$0.26 per share, against −$0.33 a year earlier (how EPS works).
Does ROIV pay a dividend?
Roivant Sciences hasn’t paid a dividend in the last twelve months.
What is ROIV’s 52-week high and low?
Over the past 52 weeks ROIV has traded as low as $17.28 and as high as $42.50. At $33.53 at the close on , it is 21.1% below that high and 94.0% above the low.
What is ROIV’s all-time high?
ROIV’s highest closing price was $41.81 on , adjusted for stock splits. At $33.53 at the close on , it is 19.8% below that record.
Has ROIV stock ever split?
No. ROIV hasn’t split since its price history begins in 2021.
How has ROIV stock performed?
Including dividends and measured to the close on , ROIV has returned +54.5% so far this year and +96.0% over the past year, and +457.0% over five years (+41.0% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Roivant Sciences in?
Roivant Sciences is in the Healthcare sector and the Biotechnology industry, and is headquartered in Bermuda.
What exchange does ROIV trade on?
Roivant Sciences trades on the Nasdaq under the ticker symbol ROIV. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.